- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin for the treatment of Type 2 diabetes
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 7, Issue 3, Pages 271-279
Publisher
Informa UK Limited
Online
2014-04-09
DOI
10.1586/17512433.2014.908703
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
- (2013) Arne Ring et al. Cardiovascular Diabetology
- Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers
- (2013) Sreeraj Macha et al. CLINICAL DRUG INVESTIGATION
- Lack of Clinically Relevant Drug–Drug Interaction Between Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, and Verapamil, Ramipril, or Digoxin in Healthy Volunteers
- (2013) Sreeraj Macha et al. CLINICAL THERAPEUTICS
- The Growing Prevalence of Type 2 Diabetes: Increased Incidence or Improved Survival?
- (2013) Nisa M. Maruthur Current Diabetes Reports
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
- (2013) S. Macha et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES OBESITY & METABOLISM
- Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes
- (2013) Matthew M. Riggs et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
- (2013) Tim Heise et al. Diabetes Therapy
- LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
- (2012) B Zambrowicz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus
- (2012) Muhammad A. Abdul-Ghani et al. Current Diabetes Reports
- Why Do SGLT2 Inhibitors Inhibit Only 30-50% of Renal Glucose Reabsorption in Humans?
- (2012) J. Liu et al. DIABETES
- Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers
- (2012) S. Macha et al. DIABETES OBESITY & METABOLISM
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
- (2012) Akiko Sarashina et al. Drug Metabolism and Pharmacokinetics
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
- (2012) Ele Ferrannini et al. Nature Reviews Endocrinology
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States
- (2011) Ian H. de Boer JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2
- (2010) Charles S. Hummel et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
- (2009) Sunil Nair et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started